Study Details

Back to Search Results

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02091999

Astellas Study ID

The unique identification code given by the study sponsor.

ASG-22CE-13-2

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Bladder Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

enfortumab vedotin

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2014 - Dec 2022

Masking

None (Open Label)

Enrollment number

213

A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site CA00001

Edmonton, Canada, T6G 1Z2

Site US00008

Tampa, United States, 33612

Site US00017

Aurora, United States, 80045

Site US00001

Seattle, United States, 98109

Site CA00010

Toronto, Canada, M5G 2M9

Site US00020

Pittsburgh, United States, 15232

Site US00005

Ann Arbor, United States, 48109

Site US00007

Miami, United States, 33136

Site US00009

Madison, United States, 53792

Site US00019

Stanford, United States, 94305

Site CA00011

Calgary, Canada, T2N 4N2

Site US00014

Baltimore, United States, 21201

Site US00021

Las Vegas, United States, 89119

Site US00025

Spokane, United States, 99208

Site US00004

Fairway, United States, 66205

Site US00024

Fairfax, United States, 22031

Site US00026

Omaha, United States, 68130

Site US00013

Philadelphia, United States, 19111

Site US00006

New Haven, United States, 06520

Site US00002

New York, United States, 10065

Site US00022

Dallas, United States, 75251

Site US00003

Detroit, United States, 48201

Site US00023

Chapel Hill, United States, 27599

Site US00018

New York, United States, 10029

Site US00027

Harvey, United States, 60426

Site US00015

Milwaukee, United States, 53226

Site US00016

Indianapolis, United States, 46202

Site US00012

Los Angeles, United States, 90033

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo